Floatz logo

Sulfadiazine

Toxoplasmosis

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Toxoplasmosis cohort.

Asset / SponsorPhaseRating
Valproic Acid
University of Pittsburgh
Phase 4BB
SPIRAMYCIN
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4BB
Pyrimethamine
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4BB

Same molecule, other indications

Sulfadiazine is also rated in:

breast carcinomaDormant
D
Indicative ·
30 / 100
View asset →
head and neck carcinomaDormant
D
Indicative ·
30 / 100
View asset →
radiodermatitisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →